Steven Stone, PhD, presents “UroVation Interview: Envision Sciences – Advancing Cancer Diagnosis and Prognosis.”
How to cite: Stone, Steven. “UroVation Interview: Envision Sciences – Advancing Cancer Diagnosis and Prognosis.” February 19, 2025. Accessed Jun 2025. https://grandroundsinurology.com/urovation-interview-envision-sciences-advancing-cancer-diagnosis-and-prognosis/
UroVation Interview: Envision Sciences – Advancing Cancer Diagnosis and Prognosis – Summary
E. David Crawford, MD, Editor in Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego, introduces Steven Stone, PhD, EVP of Research and Development at Envision Sciences, Salt Lake City, Utah. In this 10-minute talk, Dr. Stone presents an overview of Envision Sciences, a molecular diagnostics company developing immunohistochemical (IHC) biomarkers to improve risk stratification in prostate cancer.
Envision’s lead markers—EV1, EV2, and EV3—correlate with tumor metabolic states. EV1 is involved in fatty acid and insulin signaling; EV2 regulates glucose metabolism; and EV3 is associated with lipid metabolism. Their expression patterns mirror prostate cancer progression: lower-grade, androgen-responsive tumors show elevated glucose metabolism (high EV2), while higher-grade, androgen-insensitive tumors shift toward lipid metabolism (high EV3).
Stone notes that this pathology-centered approach could appeal to clinicians seeking timely and accessible prognostic tools. Compared to existing genomic tools, the IHC-based assay can be performed at diagnosis, enhancing real-time clinical decision-making. By identifying metabolic phenotypes, the assay could inform personalized treatment strategies and patient selection for metabolism-modulating drug trials.
